Shots:

• CStone is eligible to receive $200M up front and milestone along with royalties & obtains the rights to develop and commercialize CS1002 outside of Greater China. Additionally, Hengrui retains the exclusive rights for research, development, registration, manufacturing, and commercialization of CS1002 (anti-CTLA-4 mAb) in Greater China

• The agreement will strengthen Jiangsu Hengrui’s pipeline & oncology portfolio with the addition of CS1002 for the treatment of cancer

• In P-Ia/Ib study, CS1002 + CS1003 showed an positive efficacy in refractory melanoma, hepatocellular carcinoma & MSI-H/dMMR expressing tumors. The combination was generally well-tolerated

| Ref: PRNewswire | Image: Fierce Pharma